))
Promising New Treatment for Metastatic Breast Cancer
Manage episode 381837534 series 3482052
المحتوى المقدم من Breastcancer.org. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Breastcancer.org أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors’ choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy.
Listen to the podcast to hear Dr. Bardia explain:
- what an antibody-drug conjugate is
- the design of the TROPION-Breast01 study and the first results
- dato-DXd side effects
- how dato-DXd might fit into the current treatment landscape for metastatic breast cancer
303 حلقات
مشاركة
